Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clotiapine→

Clotiapine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2058-52-8
Molecular formula
C18H18ClN3S
Molecular weight
343.9 g/mol
Drug class
Dibenzothiazepine antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Antagonises central dopamine D2 receptors and also interacts with serotonin, histamine and adrenergic receptors, reducing psychotic symptoms and contributing to sedative effects.
Indications / reported uses
  • Treatment of acute psychotic disorders and schizophrenia in countries where clotiapine remains authorised; current availability and specific indications are jurisdiction-specific

Sources: NLM MeSH — Clotiapine · PubMed — Clotiapine antipsychotic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clotiapine Environmental Risk Assessment (ERA) (the Clotiapine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.